Epigenetic therapy in cancer: Perspective and paradoxes

Analytical and Quantitative Cytology and Histology

Volumn 33, Issue 5, 2011, Pages 303-304

  Filosa, Alessandra ^a   Fabiani, Andrea ^a  

^a Macerata Hospital   (Italy)

Author keywords

DNA methylation; Epigenetic regulation; Gene expression

Indexed keywords

DNA METHYLTRANSFERASE; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; NUCLEOTIDE; TRANSCRIPTION FACTOR;

CANCER CELL; CANCER RESEARCH; CANCER THERAPY; CARCINOGENESIS; CHROMATIN; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; LETTER; MYELODYSPLASTIC SYNDROME; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN MODIFICATION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EPIGENOMICS; GENETIC MARKERS; HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 84861169885     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (15)

1. Esteller M: Epigenetics in cancer. N Engl J Med 2008;358: 1148-1159.
2. Krouse RS, Alberts DS, Prasad AR, Yozwiak M, Bartels HG, Liu Y, Bartels PH: Progression of skin lesions from normal skin to squamous cell carcinoma. Anal Quant Cytol Histol 2009;31:17-25.
3. Blanca A, Vidal-Jimenez A, Campos P: Histone acetylation and chromatin pattern in cancer: A review. Anal Quant Cytol Histol 2008;30:340-341.
4. Ficarra V, Brunelli M, Cheng L, Kirkali Z, Lopez-Beltran A, Martignoni G, Montironi R, Novara G, Van Poppel H: Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. Eur Urol 2010; 58:655-668.
5. Cheng L, Williamson SR, Zhang S, Maclennan GT, Montironi R, Lopez-Beltran A: Understanding the molecular genetics of renal cell neoplasia: Implications for diagnosis, prognosis and therapy. Expert Rev Anticancer Ther 2010; 10:843-864.
6. Lopez-Beltran A, Montironi R, Egevad L, Caballero-Vargas MT, Scarpelli M, Kirkali Z, Cheng L: Genetic profiles in renal tumors. Int J Urol 2010;17:6-19.
7. Minardi D, Lucarini G, Filosa A, Milanese G, Zizzi A, Di Primio R, Montironi R, Muzzonigro G: Prognostic role of global DNA-methylation and histone acetylation in pT1a clear cell renal carcinoma in partial nephrectomy specimens. J Cell Mol Med 2009;13:2115-2121.
8. Lacy S, Lopez-Beltran A, MacLennan GT, Foster SR, Montironi R, Cheng L: Molecular pathogenesis of urothelial carcinoma: The clinical utility of emerging new biomarkers and future molecular classification of bladder cancer. Anal Quant Cytol Histol 2009;31:5-16.
9. Requena MJ, Carrasco JC, Alvarez-Kindelan J: Role of molecular markers in diagnosis and prognosis of renal cell carcinoma. Anal Quant Cytol Histol 2008;30:336-337.
10. Lopez-Beltran A, Kirkali Z, Cheng L, Egevad L, Regueiro JC, Blanca A, Montironi R: Targeted therapies and biological modifiers in urologic tumors: Pathobiology and clinical implications. Semin Diagn Pathol 2008;25:232-244.
11. Cheng L, Zhang S, Davidson DD, MacLennan GT, Koch MO, Montironi R, Lopez-Beltran A: Molecular determinants of tumor recurrence in the urinary bladder. Future Oncol 2009; 5:843-857.
12. Cheng L, Zhang S, MacLennan GT, Williamson SR, Lopez-Beltran A, Montironi R: Bladder cancer: Translating molecular genetic insights into clinical practice. Hum Pathol 2011; 42:455-481.
13. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H: Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 2006;106:1794-1803.
14. Tuma RS: Targeted epigenetic therapies: The next frontier? J Natl Cancer Inst 2010;102:1824-1825.
15. Kaiser J: Epigenetic drugs take on cancer. Science 2010;330: 576-578.